Sanofi says MS treatment reduced relapse rate

PARIS (Reuters) – Sanofi said on Friday that a trial of its multiple-sclerosis treatment teriflunomide found that a daily dose of the drug reduced the annualized rate of relapse by 36 percent compared with a placebo. Teriflunomide, marketed as Aubagio, is one of the two multiple sclerosis drugs Sanofi has in late-stage development and one of several oral MS treatments being developed by major drug companies. (Reporting By Christian Plumb)

Illinois lawmakers put off vote on pension reforms

SPRINGFIELD, Illinois (Reuters) – Divided Illinois lawmakers on Thursday put off a vote on proposed changes to its vastly underfunded public employee pension system, risking further credit rating downgrades of the state. Tom Cross, the Republican leader of the state House of Representatives, announced that too few House Democrats would support the current form of the legislation so he had agreed with Governor Pat Quinn not to call for a vote on it. “We have to be willing to find some common ground,” a weary-sounding Cross told fellow lawmakers. “We need to let emotions settle down. …

1 2 3 126